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Abstract The aim of our study was to prepare multifunc-
tional, biocompatible nanoparticles for site-specific drug
delivery. Hydrophilic nanoparticles with surface-adorned
amine, carboxyl, or aldehyde groups, to be later used for
bio-conjugation, were designed using phosphonomethyl
iminodiacetic acid (PMIDA) as the coupling agent. These
PMIDA-coated cobalt oxide nanoparticles (PMIDA-CoO)
were further functionalized with folic acid (FA), using sim-
ple technique. The particles show excellent aqueous disper-
sion stability in physiological pH without any deterioration
in hydrodynamic size. The cytotoxicity and internalization
efficiency of these nanocarriers have been evaluated on
folate receptor over expressed KB and folate receptor lower
expressed KG1a cells. Anticancer drugs such as doxorubicin
and methotrexate were successfully attached to the folic
acid-decoded PMIDA-CoO nanoparticles by simple reac-
tions. Anticancer drug-loaded nanoparticles (FA-PMIDA-
CoO) exhibit elevated cytotoxicity and induce apoptosis in
cancer cells, which were confirmed by flow cytometry. Fluo-
rescence microscopy study shows the higher amount of
internalization of the noncomplex by KB cells, which clearly
demonstrated that cells overexpressing the human folate
receptor internalized a higher level of these nanoparticles–
folate conjugates than folate receptor-negative control cells.
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PMIDA Phosphonomethyl iminodiacetic acid
PBMC Peripheral blood mononuclear cells
RhB Rhodamine B
1 Introduction
The uses of nanoparticles (NPs) with functional properties have
been widely used in a broad range of bio-applications, like drug
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and gene delivery, cell and tissue engineering, diagnostic and
therapeutic purposes, etc. (Panyam and Labhasetwar 2003;
Marin et al. 2005). Among these applications, the field of drug
delivery by NPs with specific and rapid internalization into a
target cell has immense promise (Maeda et al. 2009; Faraji and
Wipf 2009). Folic acid is a member of vitamin B family and
plays an essential role in cell survival by participating in the
biosynthesis of nucleic acids (Antony 1996). This essential
vitamin is also a high-affinity ligand that enhances the differen-
tial specificity of conjugated anticancer drugs by targeting folate
receptor (FR)-positive cancer cells (Leamon and Reddy 2004).
The folic acid (FA)-conjugated drugs can actively internalize
bound folates and folate-conjugated compounds via receptor-
mediated endocytosis (Kamen and Capdevila 1986; Leamon
and Low 1991). It has been found that FR is upregulated in
more than 90% of ovarian carcinomas. It is also found at high to
moderate levels in the kidney, brain, lung, and breast carcino-
mas, while it occurs at very low levels in most normal tissues
(Kamen and Smith 2004). The FR density also appears to
increase as the stage of the cancer increases (Elnakat and
Ratnam 2004). Various types of anticancer drugs were conju-
gated and evaluated for their biological activity (Low and
Antony 2004).
Metal NPs are the most interesting chemical elements
used as NPs because of their potential in a wide range of
biotechnological applications, especially in advanced bio-
medical application (Liong et al. 2008). Cobalt (Co) which
is mainly used as cobalt oxide has an organometal compound
or a biopolymer (Wang et al. 2005). In spite of its physio-
logical role as a cofactor of vitamin B12, cobalt cannot be
regarded only as an essential element. Cobalt oxide NPs have
anticancer activity (Papis et al. 2009) through surface mod-
ification (Chattopadhyay et al. 2012). Therefore, in the pres-
ent paper, we have focused our interest on the study of
receptor-targeted delivery of modified cobalt oxide (CoO)
NPs. We used one folate receptor over expressing cancer cell
line KB (Lee and Low 1994) and one folate receptor lower
expressing cancer cell line KG-1A (Pan et al. 2002). This
present study was aimed to develop novel and inexpensive
NPs which have anticancer activity to cancer cell in vitro as
well as serve as a drug carrier.
2 Materials and methods
2.1 Chemicals and reagents
Phosphonomethyl iminodiacetic acid (PMIDA), cobalt
chloride (CoCl2·3H2O), N-hydroxysuccinimide (NHS),
2,2-(ethylenedioxy)-bis-(ethylamine) (EDBE), 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (EDC), propidium
iodide (PI), RNase A, 3-(4,5-dimethyl-2-thiazolyl)-2,5-
diphenyl-2H-tetrazolium bromide (MTT reagent), rhodamine
B (RhB), Histopaque 1077, ethidium bromide (EtBr), folic
acid, doxorubicin (DOX), and methotrexate (MTX) were
procured from Sigma (St. Louis, MO, USA). Minimum es-
sential medium (MEM), RPMI 1640, fetal bovine serum
(FBS), penicillin, streptomycin, sodium chloride (NaCl), so-
dium carbonate, sucrose, Hank’s balanced salt solution, and
ethylenediaminetetraacetate were purchased from HiMedia,
India. Tris–hydrochloric acid (HCl), Tris buffer, KH2PO4,
K2HPO4, HCl, formaldehyde, alcohol, and other chemicals
were procured from Merck Ltd., SRL Pvt. Ltd., Mumbai,
India. Commercially available dimethyl sulfoxide (DMSO)
was procured from HiMedia, India and was purified by vac-
uum distillation over KOH. All other chemicals were from
Merck Ltd., SRL Pvt., Ltd., and were of the highest purity
grade available.
2.2 Synthesis of PMIDA-coated cobalt oxide NPs and folic
acid-coated NPs
CoO NPs were synthesized by calcinated method
(Chattopadhyay et al. 2012) followed by conjugation with
PMIDA. To conjugate the nanoparticles with folic acid, FA
was dissolved in ∼10 ml of DMSO (0.025 mM) due to the
limited solubility of FA in aqueous medium. FA-EDBE was
synthesized according to our previously reported protocol
(Das et al. 2008). The resulting solution was then mixed with
an aqueous solution of EDC (75 mM) and NHS (15 mM).
The pH of the solution was then adjusted to ∼8 by dropwise
addition of pyridine. An aqueous dispersion of ∼10 mg of
PMIDA-functionalized nanoparticles was added to it and the
reaction mixture was stirred overnight at 37 °C in dark.
Following FA conjugation, the modified particles were again
isolated with a rare earth magnet, washed three times with
deionized water, and redispersed in PBS (Das et al. 2008).
2.3 Preparation of folic acid-coated fluorescent NPs
Five milligrams of folic acid-decorated cobalt oxide
nanoparticles was dispersed in 5 ml distilled water. RhB
was added with FA-PMIDA-CoO NPs. The resulting sus-
pension was stirred in the dark for 12 h. Particles were
recovered by centrifugation and washed thoroughly with
Millipore water (Rho-FA-PMIDA-CoO NPs).
2.4 Preparation of DOX-loaded FA-PMIDA-CoO
nanoparticles
FA-PMIDA-CoO nanoparticles immobilized with DOX were
prepared through the following process. TheDOX (0.5mg/ml)
in water solution was introduced in a nanoparticles suspension
(1 mg/ml) and stirred for 24 h. The suspension was then
centrifuged at 15,000 rpm for 20 min to precipitate the
nanoparticles and decanted. The process was repeated three
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times to remove any free DOX in the suspension. The amount
of loaded DOX was measured by spectrophotometrically at
481 nmwith a UV-1800 spectrophotometer (Shimadzu) (Sahu
et al. 2010). The percentage of encapsulation (EE%) was
calculated from following equation:





2.5 Preparation of MTX-loaded FA-PMIDA-CoO
nanoparticles
FA-PMIDA-CoO nanoparticles immobilized with MTX
were prepared through the following process. The MTX
(conc. 0.5 mg/ml) in water solution was introduced in a
nanoparticle suspension (1 mg/ml) and stirred for 24 h. The
suspension was then centrifuged at 15,000 rpm for 20 min to
precipitate the nanoparticles and decanted. The process was
repeated three times to remove any free MTX in the suspen-
sion. The amount of loaded MTX was measured spectropho-
tometrically at 270 nm with a UV-1800 spectrophotometer
(Shimadzu) (Sahu et al. 2010). The percentage of encapsu-
lation (EE%) was calculated from following equation:





2.6 In vitro drug release
In order to study the DOX and MTX release behavior, 2.5 mg
of DOX-FA-PMIDA-CoO NPs and MTX-FA-PMIDA-CoO
NPs (0.5 mg/ml) was suspended in 5 ml of PBS. The solution
pH was adjusted to 3, 5, and 7.4 using 0.1 M HCl and NaOH.
Following incubation for 8, 12, 24, and 48 h, the nanoparticle
suspensions were isolated and the MTX cleaved from
nanoparticles was then quantified spectrophotometrically at
481 and 270 nm, respectively (Mohapatra et al. 2011).
2.7 Characterization
2.7.1 Characterization of FA-PMIDA-CoO NP
DLS analysis Dynamic light scattering (DLS) analysis was
done by Zetasizer Nano ZS (Malvern Instruments) according
to the method of Chakraborty et al. (2010) with some mod-
ifications. The NPs were (100 μg/ml) sonicated for 2 min
and dynamic particle sizes were measured suspending two
drops of aqueous suspension of NPs in 10 ml of Millipore
water. When particle was completely dispersed in water, then
particles were analyzed with a dynamic light scattering ana-
lyzer. The experiments were repeated several times to get
average size of nanoparticles.
SEM micrograph The particle size and microstructure were
studied by scanning electron microscopy (Hitachi S-3400N)
according to the method of Ghosh et al. (2011) with some
modifications. In brief, FA-PMIDA-CoO NPs were
suspended in deionized water at a concentration of 1 mg/ml
then the sample was sonicated using a sonicator bath until the
sample formed a homogenous suspension. For size measure-
ment, sonicated stock solution of all cobalt oxide NPs (0.5-
mg/ml) was diluted 20 times. SEM was used to characterize
the size and shape of the cobalt oxide NPs. A drop of
aqueous cobalt oxide NP suspension was placed onto
carbon-coated copper grid and this was dried in air to get
SEM image.
FTIR analysis of folic acid conjugation The conjugation of
folic acid (FA) with PMIDA-CoO NPs was investigated by
Fourier transform infrared (FTIR) model PerkinElmer
Spectrum RXIFT-IR System according to the method of
Ghosh et al. (2011) with some modifications. In brief,
1.0 mg sticky mass of FA-PMIDA-CoO NPs with 100 μl
KBr medium and a thin film was prepared on the NaCl
plate by drop casting method and under atmosphere
separately. The FTIR value was taken within 400 cm−1
to 4000 cm−1 (wave numbers).
Surface chemistry of drug-loaded FA-PMIDA-CoO NP The
conjugation of drug with FA-PMIDA-CoO NPs was inves-
tigated by the FTIR with a model Thermo Nicolet Nexus
model 870 according to the method of Ghosh et al. (2011)
with some modifications. In brief, 1.0 mg sticky mass of
DOX-FA-PMIDA-CoO NPs and MTX-FA-PMIDA-CoO
NPs with 100 μl KBr medium and a thin film was prepared
on the NaCl plate by drop casting method and under atmo-
sphere separately. The FTIR value was taken within 500 to
4,000 cm−1 (wave numbers).
2.8 Solubility and stability of FA-PMIDA-CoO NPs
Stability assessments were performed at different pH of
phosphate buffer varying from pH 3 to 7.4. For all measure-
ments, the concentrations of particles were maintained at
3 mg/ml and folic acid release was measured spectrophoto-
metrically at 270 nm.
2.9 Plasma protein binding assay
Plasma protein binding was determined by using human
plasma according to Patila et al. (2007). Human plasma
samples were obtained from eight healthy individuals
according to institutional bioethics approval. Two milli-
grams per milliliter of nano-FA-PMIDA-CoO was mixed
with 5 ml of 50 mM PBS and 0.5 ml of human plasma
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(8 mg/ml) was added together and stirred with vigorously
within a shaking incubator for 24 h at 37 °C. The
nanoparticles were centrifuged at 10,000 rpm for 10 min
and sup was used to determine the protein concentration by
Lowry et al. (1951). Plasma without NPs was used as a
control to ensure that there was no protein precipitation.
2.10 Separation of PBMCs and macrophages
Fasting blood samples were collected from all groups of
individuals satisfying the Helsinki protocol. The lympho-
cytes were isolated from heparinized blood samples
according to the method of Hudson and Hay (1991). Blood
was diluted with phosphate-buffered saline (pH 7.0) in equal
ratio and then layered very carefully on the density gradient
(Histopaque 1077) in 1:2 ratio and centrifuged at 1,400 rpm
for 40 min, and the white milky layer of mononuclear cells
was carefully removed and cultured in RPMI 1640 medium
supplemented with 10 % fetal calf serum, 100 units/ml pen-
icillin and 100 μg/ml streptomycin, 4 mM L-glutamine under
5 % CO2, and 95 % humidified atmosphere at 37 °C for 2 h.
The non-adherent layer of the cultured cells was washed twice
with the PBS and centrifuged at 2,000 rpm for 5 min to get the
required pellet of PBMCs. The adherent layer of the cultured
cells was treated with 0.25 % trypsin in PBS for 3 min at
37 °C, washed twice with the PBS, and centrifuged at
2,000 rpm for 5 min to get the required pellet of macrophages.
2.11 Cell culture
The normal human lymphocytes and macrophages, KB and
KG1a cell lines, were cultivated for in vitro experiments. Cell
lines were obtained from the National Centre for Cell Sci-
ences, Pune, India. It was cultured in RPMI 1640 medium and
MEM supplemented with 10 % fetal calf serum, 100 units/ml
penicillin and 100 μg/ml streptomycin, 4 mM L-glutamine
under 5 % CO2, and 95 % humidified atmosphere at 37 °C.
2.12 Preparation of drug
Several doses of FA-PMIDA-CoO NPs (1–25 μg/ml) were
prepared using sterile phosphate-buffered saline (pH 7.4). In
this study, all these doses were charged against normal and
cancer cell line for evaluation of in vitro anticancer activity.
2.13 In vitro cytotoxicity assay
Each type of cells was divided into nine groups. Each group
contained six Petri dishes (2×105 cells in each). The cells of
each Petri dish of control and experimental groups were
maintained in MEM and RPMI 1640 media, where it is appli-
cable, supplemented with 10 % FBS, 50 μg/ml gentamycin,
50 μg/ml penicillin, and 50 μg/ml streptomycin at 37 °C in a
95 % air/5 % CO2 atmosphere in CO2 incubator. From 10
5
cells/ml cell suspension, 180 ml cell suspension was seeded
into each well of 96-well tissue culture plates and incubated for
24 h followed by the addition of FA-PMIDA-CoONPs, DOX-
FA-PMIDA-CoO NPs, and MTX-FA-PMIDA-CoO NPs at
concentrations from 1 to 25 μg/ml and was incubated for
24 h at 37 °C in a humidified incubator maintained with 5 %
CO2. The cell proliferation was estimated by MTT assay
(Chattopadhyay et al. 2012).
2.14 Intracellular uptake study
Nanoparticle uptake by KB and KG1a cells was studied by
fluorescence microscopy methods according to our previous
laboratory report (Sahu et al. 2010). Cells (2×105) were
seeded into 35 mm cell culture plates and were incubated with
25 μg/ml FA-PMIDA-CoO-RhB/DOX-FA-PMIDA-CoO-
RhB/MTX-FA-PMIDA-CoO-RhB for fluorescence micros-
copy. Then, the cells were allowed to adhere to a glass cover-
slip followed by incubation for 4 h at 37 °C in a humidified
incubator maintained with 5 % CO2. Fluorescence images
were acquired with 540 nm laser for differential interference
contrast microscopy and 625 nm lasers for RhB excitation and
emission on an Olympus research phase contrast with fluores-
cence microscope (model CX40; Olympus).
2.15 Interaction of particles with macrophages in vitro
Macrophages isolated from normal human blood were cul-
tured in complete RPMI media and allowed to adhere to the
Petri plate surface. Macrophages (5×105) in 2 ml complete
RPMI media and 50 μg of PMIDA-CoO NP-RhB/FA-
PMIDA-CoO NP-RhB were added and incubated for 12 h
at 37 °C in a humidified incubator. After incubation, the Petri
plates were washed with warm PBS and phagocytic uptake
was quantified using phase-contrast fluorescence inverted
microscope at ×400 magnifications (Das et al. 2008).
2.16 Apoptosis study by conventional EtBr staining
Apoptosis study was done according to Ribble et al. (2005),
briefly suspension cells were harvested and transferred to a
15-ml tube with Dulbecco’s phosphate-buffered saline. Cells
were pelleted by centrifugation at 1,000 rpm for 5 min and
washed with 1 ml of cold PBS once. Cell pellets were then
resuspended in 100 μl cold PBS and 5 μl EtBr dye was
added. Stained cell suspension (10 μl) was placed on a clean
microscope slide and covered with a coverslip. The cells
were viewed and counted using a phase-contrast fluores-
cence inverted microscope at ×400 magnification with exci-
tation filter 480/30 nm. Pictures were taken with a Nikon
COOLPIX digital camera. Tests were done in triplicate,
counting a minimum of 100 total cells each.
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2.17 Detection of cellular apoptosis by flow cytometric
analysis using propidium iodide
Cell apoptosis was measured using propidium iodide staining
and analysis by flow cytometry (Roa et al. 2009). After the
treatment schedule, the cells were scraped and centrifugedwith
the supernatant medium at 3,500 rpm for 5 min. Following
washes, cells were resuspended in PBS and fixed in 70 %
ethanol for 1 h on ice. Fixed cells were washed with PBS and
stained with propidium iodide (5 μg/ml) solution containing
ribonuclease (RNase) (50 μmol/L) for 30 min at room temper-
ature. Then, the cells were analyzed on a Becton Dickinson
FACSCalibur flow cytometer. The G0/G1 population (apopto-
tic cells) of the cells was determined by CellQuest software.
2.18 Statistical analysis
The data were expressed as mean ± SEM (n=6). Compari-
sons between the means of control and treated group were
made by one-way ANOVA test (using a Statistical Package,
Origin 6.1, Northampton, MA, 01060, USA) with p<0.05 as
a limit of significance.
3 Result and discussion
3.1 Synthesis of FA-PMIDA-CoO nanoparticles
FA-PMIDA-CoO NPs were synthesized according to the
method outlined in Scheme 1. –NH2 group of folic acid
and carboxylic group (−COOH) of PMIDA-CoO NPs were
connected through the end-amino groups. Folic acid was
chosen as a linker in order (1) to get optimized length of
linker to reach accessible receptor sites, (2) to increase the
water solubility, and (3) to make the folate conjugate system
biocompatible.
3.2 Solubility and stability assessment
PMIDA-CoO NPs are insoluble in water, whereas FA-
PMIDA-CoO NPs form a semitransparent salutation with
water even at different pH. The stability of FA-PMIDA-
CoO NPs at different pH was estimated spectrophotometri-
cally at 270 nm. Our result shows that FA-PMIDA-CoO NPs
shows a very good solubility at pH 2.0 to pH 8.0. PMIDA-
CoO NPs are strongly hydrophobic in nature and our previ-
ous studies had focused on the biological activities of this
water-insoluble particle (Chattopadhyay et al. 2012). To
overcome this problem, we had to change sample prepara-
tion approaches. We use folic acid as a ligand on PMIDA-
coated CoO NPs. The presence of folic acid on outer surface
results in water solubility of the metal NPs by visual obser-
vation. Solubility in aqueous medium may be advantageous
for potential applications of metal NPs in catalysis or bio-
medicine (Brunner et al. 2006; Uzun et al. 2008). The sta-
bility of FA-PMIDA-CoO NPs at different pH was estimated
spectrophotometrically at 270 nm. Our result shows that FA-
PMIDA-CoO NPs show a very good stability at physiolog-
ical pH. Amide group is more of a polarizing group than acid
group. When amide compound is dissolve in water, it fully
Cobalt oxide nanoparticles
PMIDA




Scheme 1 Structure of FA-
PMIDA-CoO NPs
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coordinates with water through “−H” bonding via “N” atom.
As a result, it is very much soluble in water. Each terminal –
NH2 group also forms –H bond with water. So, the compound
becomes soluble in water (Fig. 1a).
3.3 Dynamic light scattering experiment
The size distribution of hydrophilic FA-PMIDA-CoO NPs in
aqueous medium was characterized by DLS. The mean size
a b



















































Fig. 1 Water solubility of only PMIDA-cobalt oxide nanoparticles and
FA-PMIDA-cobalt oxide nanoparticles (a); size determination of FA-
PMIDA-cobalt oxide nanoparticles (b), DOX-FA-PMIDA-cobalt oxide
nanoparticles (c), and MTX-FA-PMIDA-cobalt oxide nanoparticles (d)
by dynamic light scattering. SEM images of PMIDA-coated cobalt
oxide nanoparticles (e)
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of nanoparticles in aqueous solution was determined, which
ranges from 200 to 240 nm as shown in Fig. 1b. An inves-
tigation on hydrodynamic size of drug conjugates −MTX
and −DOX was carried out through dynamic light scattering.
DOX-FA-PMIDA-CoO shows presence of stable nano-
aggregated particles with a hydrodynamic size of
230±30 nm (Fig. 1c) and MTX-FA-PMIDA-CoO of
225±30 nm (Fig. 1d). The stability of drug-conjugated par-
ticles was investigated by measuring the hydrodynamic size
which shows that there is almost no change of hydrodynamic
size. This observation implies that such stable drug conjugates
can be circulated in the bloodstream for a long period.
3.4 SEM morphology of FA-PMIDA-CoO nanoparticles
The SEM morphology of FA-PMIDA-CoO NPs shows hav-
ing nearly spherical geometry with a mean size of less than
100 nm. The result was represented in Fig. 1e. The presence of
some bigger particle should be attributed to be aggregating or
overlapping of some small particles. The observed NP size
was approximately larger than the hydrodynamic diameter
obtained from the DLS experiment. SEM imaging describes
the size in the dried state of the sample, whereas DLS mea-
sured the size in the hydrated state of the sample. So, the size
measured by DLS was a hydrodynamic diameter and always
larger than the SEM image. However, one has to bear in mind
that by SEM, we image single particles, while DLS gives an
average size estimation, which is biased toward the larger size
end of the population distribution.
3.5 Fourier transform infrared spectroscopy
Conjugation of folic acid with PMIDA-coated CoO NPs is
investigated by FTIR spectroscopy. The FTIR spectrum of
folic acid derivative shows the various functional groups of
the molecules. The FTIR spectrum of pure CoONP, PMIDA,
and PMIDA-coated CoO NPs were published in our previ-
ous lab report (Chattopadhyay et al. 2012). The comparisons
of FTIR spectrum of folic acid (Fig. 2a) and FA-PMIDA-
CoO NPs are shown in Fig. 2b. FTIR spectra show basic IR
band characteristics of CoO at 566 cm−1, which indicate the
presence of CoO vibration and a broad band around
3,440 cm−1, indicative of the presence of –OH groups on
the nanoparticle surface. The important areas of examination
are in the 3,000–1,500-cm−1 region. This region is known as
the functional group region. In FA-PMIDA-CoO, NPs show
the characteristic band of folic acid. After conjugation of
PMIDA-CoO NPs with folic acid, the spectrum of resultant
molecules shows not only the characteristic band of the
original band of CoO NPs and PMIDA-CoO NPs, but also
the characteristic peak of the folic acid at 1,653 cm−1
(−CONH band) and 1,023 cm−1 (−NH band). Furthermore,
the absorption of amide band at 1,023 cm−1 increases, which
may be due to the formation of the amide linkage between
the amino group of the folic acid and PMIDA-CoO NPs
(Fig. 2b). The FTIR spectra of the DOX (ESM 1) particles
show strong absorption at 500–600 cm−1, characteristic vi-
bration of M–O in the ferrite lattice (Fig. 2c). In addition to
this, the intensification of band at 2,912 cm−1 along with the
C=O stretching at 1,645 cm−1 indicates that MTX has been
conjugated to –NH2-terminated particles through –CONH
linkage. Similarly, the successful attachment of MTX (ESM
1) was also established using FTIR (Fig. 2d).
3.6 In vitro drug release assay
In vitro drug release experiments carried out with MTX and
DOX-conjugated NPs in PBS buffer medium at pH 3, pH 5,
and pH7.4were investigated in two separate batches. BothMTX
and DOX showed typical release profiles. MTX showed rapid
release rates from the beginning followed by a sustained release
pattern of 94 % (pH 3) and 83 % (pH 5), and in PBS (pH 7.4), it
was 71% after 48 h (Fig. 2e). But in the case of DOX, a different
release behavior was observed. It was observed that the release of
DOX fromFA-PMIDA-CoO-DOXNPs in the buffer medium of
PBS was 78 % (pH 3) and 58 % (pH 5), whereas in PBS (pH
7.4), it was 45% after 48 h. The overall release rates were higher
and lower pH (7.0 and 3.0) and less release was observed in
physiological pH. This is because the drugs have been covalently
grafted through amide bonds and protonation of amino groups at
lower pHwhich loosens nanoparticle structure (Sahu et al. 2010).
These pH-sensitive cleavages of amide bonds release the drug
(Fig. 2e). The extracellular pH of tumors is slightly more acidic
than the blood and normal tissue (Engin et al. 1995; Van Sluis
et al. 1999). It was observed that at acidic pH (pH 5.0),MTX and
DOX release was more than physiological pH. In addition, it is
proposed that nanoparticles are internalized by cells via an
endocytosis process (Park et al. 2006; Decuzzi and Ferrari
2007). The endocytic pathway begins near the physiological
pH of 7.4; it drops to a lower pH of 5.5–6.0 in endosomes and
approaches pH 4.5–5.0 in lysosomes (Mellman et al. 1986).
Therefore, polymeric nanoparticles that are responsive to pH
can be designed to selectively release their payload in tumor
tissue or within tumor cells.
3.7 Plasma protein binding activity
The surface chemistry of biomaterials has great effects on the
protein adsorption process. Some factors such as electrostatic
interaction, hydrophobic interaction, and specific chemical in-
teractions between the protein and the adsorbent play important
roles. The binding of proteins to FA-CoO NP is shown in
Fig. 3b, c. Our result supported that NPs can bind many differ-
ent plasma proteins. The knowledge of adsorption of albumin to
the NPs is very important because once in the body, blood
proteins will adsorb to the particles and cells will then react
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with the adsorbed proteins on the particles which will ultimately
affect cellular uptake and can alter biochemical activity.
3.8 In vitro toxicity studies
The toxicity of the FA-PMIDA-CoO NPs is checked towards
normal human lymphocytes in vitro. FA-PMIDA-CoO NP-
mediated cytotoxicity to these normal cells was measured by
MTT assay (Fig. 4a). Here, we investigated the effect of FA-
PMIDA-CoO NPs, FA-PMIDA-CoO-DOX NPs, and FA-
PMIDA-CoO-MTX NPs on the proliferation of FR (+) KB
cells and FR (−) KG1a cells in vitro. It is observed from our
experiment that PMIDA-coated CoO NPs kill the KB cells by
12.20, 23.58, 35.78, and 58.18 and KG1a cells by 11.58,
22.36, 34.82, and 55.27 %, respectively, at a dose of 1, 5,
10, and 25 μg/ml (significant at the level of p<0.05) (Fig. 4b).
Whereas FA-PMIDA-CoO NPs are nontoxic at the dose of 1,
5, 10, and 25 μg/ml (Fig. 4a). So, it is observed from our
results that FA-PMIDA-CoO NPs have no effect on KB and
KG1a cell lines as well as normal human immunocytes.
It was observed that DOX-FA-PMIDA-CoO NPs and
MTX-FA-PMIDA-CoO NPs induce a significant change in
the proliferation with a concentration up to 25 μg/ml with























 MTX (PH3)  MTX (PH5)  MTX(PH7)
 DOX (PH3)  DOX (PH5)  DOX (PH7)e
Fig. 2 FTIR spectra of only folic acid (a), FA-PMIDA-cobalt oxide nanoparticles (b), DOX-FA-PMIDA-CoO NP (c), and MTX-FA-PMIDA-CoO
NP (d). Percentage of drug release at different pH (e)
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an efficient drug carrier. Subsequently, the proliferation of
KB and KG1a cells reduced significantly in the presence of
DOX-FA-PMIDA-CoO NPs and MTX-FA-PMIDA-CoO
NPs at 1–25 μg/ml in respect to FA-PMIDA-CoONPs alone.
This is possibly attributable to the affinity of folic acid
towards the folate receptor, which results in higher intake
a
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 % of Control Human Plasma
Fig. 3 Percentage of folic acid
binding (a), percentage of
protein binding with FA-
PMIDA-CoO nanoparticles (b),
and percentage of protein
release in sup (c)
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 Control  1 µg/ml  5 µg/ml
 10 µg/ml  25 µg/mlc
Fig. 4 Cytotoxicity of FA-
PMIDA-CoO nanoparticles
towards normal human immune
cells (d), cytotoxicity of
PMIDA-CoO nanoparticles and
FA-PMIDA-CoO nanoparticles
towards KB and KG1a cell lines
(a), and cytotoxicity of DOX-
FA-PMIDA-CoO nanoparticles
and MTX-FA-PMIDA-CoO
nanoparticles towards KB and
KG1a cell lines (b). n=6; values
are expressed as mean ± SEM.
Asterisk indicates the significant
difference as compared to
control group
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of DOX-FA-PMIDA-CoO and MTX-FA-PMIDA-CoO par-
ticles as compared to FA-PMIDA-CoO NPs. However, the
proliferation of KB and KG1a cells reduced drastically in a
dose-dependent manner in the presence of drug-conjugated
NPs. This is attributed to the active uptake of nanoparticles in
a folate receptor-mediated endocytosis that interfered with
the cell proliferation, which ultimately results in the target-
specific delivery of drugs to cancer cells (Fig. 4c). DOX-FA-
PMIDA-CoO particles kill KB cells by 28.06, 55.27, 75.43,
and 85.16 % and KG1a cells by 15.83, 26.71, 36.63, and
47.71 %; MTX-FA-PMIDA-CoO kills KB cells by 27.92,
52.64, 72.86, and 85.29 % and KG1a cells by 14.54, 25.29,
36.2, and 48.65 % at the dose of 1–25 μg/ml.
3.9 Intracellular uptake by fluorescence imaging
Nanoparticles binding to the plasma membrane and cellular
uptake are probably a necessary condition for its exertion of
cytotoxicity. We have shown that drug-loaded FA-PMIDA-
CoO NPs were internalized by cancer cells in in vitro cul-
tures and the alteration of cellular structure was observed
(Fig. 5a, d). This internalization might be due to the receptor-
mediated endocytosis (Mohapatra et al. 2007). KB cells
express greater amount of FR and the internalization of
drug-conjugated NPs was higher, but KG-1A cells express
lower FR on cell surfaces and internalization of drug-
conjugated NPs was lower than the KB cells. For this reason,
KB cells are more susceptible to drug-conjugated NPs than
KG-1A cells.
3.10 Phagocytosis of particles by macrophages in vitro
Macrophages are the primary phagocytes in the body,
which play a critical role in the clearance of particles
delivered into the body’s circulation. The phagocytosis
of FA-PMIDA-CoO NPs by macrophages was studied
Fig. 5 Fluorescence image of
the RhB-DOX-FA-PMIDA-
CoO/RhB-MTX-FA-PMIDA-
CoO-treated KB (a, b) and
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in vitro. It was observed that phagocytosis of the folate-
adorned nanoparticles by macrophages was appreciably
lower, as compared to the uptake by KB cells (Fig. 5e,
f). The uptake level is even higher when PMIDA-CoO
NPs have been used (Fig. 5e). It should, however, be
noted that, with the present size and surface chemistry
of nanoparticles, the phagocytosis by macrophages will
be low compared to folate receptor-mediated endocyto-
sis by cancer cells. The present finding is also consis-
tent with an earlier report on the phagocytosis of folate-
modified nanoparticles (Das et al. 2008). FR is known
to be upregulated in a cancer cells, whereas in normal
cells, FR is only minimally distributed (Kamen and
Smith 2004). Our result showed that higher amount of
FA-PMIDA-CoO NPs was internalized into the KB cells
and lower amount into FR lower expressing cells. For
that reason, FA-PMIDA-CoO NPs did not produce any
adverse effects towards normal cells up to selected dose.
3.11 Cellular apoptosis analysis by EtBr staining and flow
cytometric study
To investigate whether FA-PMIDA-CoO NPs are associated
with the induction of cellular apoptosis, after the treatment
schedule, the phenotypic characteristics of cells were evalu-
ated by fluorescence microscopic examination of overall
Fig. 6 Fluorescence image of
the EtBr-stained KB after DOX-
FA-PMIDA-CoO (a, b) and
MTX-FA-PMIDA-CoO (c, d)
and the image of the EtBr-
stained KG1a cells after DOX-
FA-PMIDA-CoO (e, f) and
MTX-FA-PMIDA-CoO (g, h).
Each of the figures mentioned
here was represented in gray
scale and fluorescence scale,
respectively
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morphology at a magnification of ×50. Ethidium bromide
was used to visualize condensed chromatin of apoptotic dead
cells. The treated cells showed red color because ethidium
bromide stains fragmented nuclear chromatin in apoptotic
cells (Fig. 6), but it is excluded by live cells (Meiyanto et al.
2007).
A quantitative evaluation of DOX-FA-PMIDA-CoO NP-
and MTX-FA-PMIDA-CoO NP-mediated cell death was
carried out through cell cycle analysis using standard PI
staining flow cytometry. Figure 7 shows an increase in cells
in the sub-G0/G1 phase (P1) with an increase in fragmented
DNA. The anticancer effect of drug-loaded CoO NPs is due
to increasing chromatin condensation and DNA fragmenta-
tion. DNA fragmentation in two cell lines can be seen on the
results of staining with PI, which indicates the occurrence of
apoptosis (Fig. 7), and characteristic features of chromatin
condensation and fragmentation of DNA (Qu et al. 2007).
DOX and MTX are two potential anticancer drugs.
Therefore, we intended to study whether the targeted deliv-
ery of DOX and MTX in a folate receptor-mediated method
could result in a similar cell fate. Hence, we investigated the
nuclear fragmentation which is a hallmark of apoptosis with
the cells treated with DOX- and MTX-loaded particles. With
an increasing dose of the DOX-FA-PMIDA-CoO NPs and
MTX-FA-PMIDA-CoO NPs, an increase in the formation of
fragmented nuclei containing condensed nuclear material
was observed in fluorescence microscopy after nuclear stain-
ing with EtBr.
4 Conclusion
In this study, a simple process has been developed to syn-
thesize FA-PMIDA-CoO NPs. This nano polymeric carrier
system shows excellent solubility in aqueous medium with
















Fig. 7 DOX-FA-PMIDA-CoO NP-induced cellular apoptosis analysis
in KB and KG1a cell lines by flow cytometry using propidium iodide.
Here, a (KB cells) = control, b and c = KB cell + 10 and 25 μg/ml DOX-
FA-PMIDA-CoO, respectively, d and e = KB cells + 10 and 25 μg/ml
MTX-FA-PMIDA-CoO, respectively; nanoparticles induced cellular
apoptosis analysis KG1a cell lines by flow cytometry using propidium
iodide. Here, f = control, g and h = KG1a cell + 10 and 25 μg/ml DOX-
FA-PMIDA-CoO, respectively, i and j = KG1a cells + 10 and 25 μg/ml
MTX-FA-PMIDA-CoO, respectively. Here, P1 = G0/G1 phase (apo-
ptotic phase), P2 = S phase (synthesis phase), P3 = M phase
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test using an MTT assay method showed that these FA-
PMIDA-CoO NPs have no adverse effect on normal cells.
Surface functionalization with –COOH and –NH2 groups
facilitates conjugation of nanoparticles with anticancer drugs
through amide which is efficiently uptaken by cancer cells.
The data presented here suggest that further in vivo studies
are warranted to define the therapeutic index of the tumor-
targeting polymeric carrier and will constitute the basis for
the next-generation drug development.
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